• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

5 Healthy Eating Habits To Adopt This Year
By Cynthia Sass, MPH, RD Nutrition is a hot topic these days, yet many of my clients still struggle with consistently following through with "the basics," and the stats show that missing the mark on many healthy habits is the norm. For example, the median daily intake of produce for U.S. adults is 1.1 servings of fruit and 1.6 servings of veggies, far below the minimum recommended five daily servings. If you're going to set just one goal for 2015, I think eating more produce should be it, but I've also listed four others below. I know you've heard them before, but they are without a doubt the most tried-and-true, impactf...
Source: Healthy Living - The Huffington Post - January 11, 2015 Category: Consumer Health News Source Type: news

Rooibos: Better Than Green Tea For Many Reasons
When I hiked Table Mountain on my last trip to South Africa, the locals told me about an herb that is better than green tea that kept them disease-free. African Bushmen have used this herb since before recorded history, but it’s still pretty rare here in America. Studies on this plant are being done all over the world. But not in the U.S. Because Big Pharma and the FDA aren’t interested in a natural cure that can’t be patented — or profited from. What is This South African Herb? I’m talking about an herb called Rooibos — or red bush in Afrikaans. Rooibos (pronounced roy-boss) provides a whole lo...
Source: Al Sears, MD Natural Remedies - May 27, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Natural Cures Source Type: news

Turmeric: Nature ’s Miracle Root for Disease
My friends Lelir and Westi in Bali don’t like to go to doctors. Nature is their pharmacy. You see, Lelir is a Balian. That means “herbal healer.” And Westi’s plantation is bursting with healing plants.  But one plant stands out above all the others. Lelir uses it to make a daily immune-boosting elixir as well as an anti-aging facial scrub. Balians use it as an antibiotic and for liver support. They boil it with milk and sugar to treat the common cold and allergies. Rural doctors make it into a paste with lime to ease sore joints. They make drinks to treat fevers and stomach pain. They mix it wi...
Source: Al Sears, MD Natural Remedies - September 20, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Natural Cures Source Type: news

Dioscin: a diverse acting natural compound with therapeutic potential in metabolic diseases, cancer, inflammation and infections
Publication date: Available online 10 October 2018Source: Pharmacological ResearchAuthor(s): Xufeng Tao, Lianhong Yin, Lina Xu, Jinyong PengAbstractCurrently, the numbers of patients with cancer, fibrosis, diabetes, chronic kidney disease, stroke and osteoporosis are increasing fast and fast. It’s critical necessary to discovery lead compounds for new drug development. Dioscin, one active compound in some medicinal plants, has anti-inflammation, immunoregulation, hypolipidemic, anti-viral, anti-fungal and anti-allergic effects. In recent years, dioscin has reached more and more attention with its potent effects to treat ...
Source: Pharmacological Research - October 11, 2018 Category: Drugs & Pharmacology Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news